Scienture (NASDAQ:SCNX) Posts Quarterly Earnings Results, Misses Expectations By $1.48 EPS

Scienture (NASDAQ:SCNX) posted its earnings results on Monday. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($1.48), FiscalAI reports. The company had revenue of ($0.17) million during the quarter, compared to analysts’ expectations of $0.49 million.

Scienture Stock Down 42.2%

NASDAQ:SCNX opened at $0.24 on Tuesday. The stock’s 50 day moving average price is $0.44 and its 200 day moving average price is $0.61. The company has a market capitalization of $9.79 million, a PE ratio of -0.24 and a beta of 3.00. Scienture has a 52-week low of $0.24 and a 52-week high of $2.60.

Analysts Set New Price Targets

SCNX has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a report on Friday. Maxim Group started coverage on shares of Scienture in a report on Tuesday, February 24th. They issued a “buy” rating and a $1.50 target price for the company. Finally, Wall Street Zen upgraded shares of Scienture to a “hold” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $1.50.

Institutional Investors Weigh In On Scienture

An institutional investor recently raised its position in Scienture stock. Geode Capital Management LLC increased its holdings in Scienture Holdings, Inc. (NASDAQ:SCNX) by 264.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 316,201 shares of the company’s stock after acquiring an additional 229,398 shares during the quarter. Geode Capital Management LLC owned approximately 0.78% of Scienture worth $161,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.68% of the company’s stock.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.